Amgen Inc (AMGN) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Total Revenue Chart for Amgen Inc

Amgen Inc (AMGN) revenue for FY2025 was USD 36.7B, a 9.9% change from FY2024. Amgen Inc's revenue grew from USD 21.1M in 1985 to USD 36.7B in 2025 (174028.0% over 40 years). Earnings per share grew from USD 1.05 in 2000 to USD 12.11 in 2022 (1053.9%). Revenue compound annual growth rate: 5-year CAGR of 7.6%, 10-year CAGR of 5.4%, 20-year CAGR of 5.6%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$251.94B
Implied Share Price
$466.01
Enterprise Value
$295.25B
Revenue (TTM)
$38.09B
EBITDA
$17.27B
Profit Margin
22.95%
Trailing P/E
28.94
Forward P/E
18.90
Price/Book (MRQ)
21.56
Price/Sales (TTM)
6.61
EV/EBITDA
16.75
EV/Revenue
7.75
Dividend Yield
2.13%
Book Value
$21.62
Free Cash Flow (FY2025)
$8.10B
Free Cash Flow Yield
3.22%

Snapshot as of 2nd November 2026 — not point-in-time controlled, may lag the live market by a few days.